Vestal Point Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001974915
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 81 positions · Total reported value $2.21B · Top-10 concentration 38.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 14 new · 20 cut · 19 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, Vestal Point Capital, LP disclosed 81 equity positions with a combined reported value of $2.21B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 38.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were ASND ($119.29M), ACLX ($102.62M), NUVL ($95.13M). By sector, the heaviest allocations are Health Care 78.0%, Industrials 2.0%. Versus the prior quarter, allocation shifted toward Health Care (+8.5pp) and away from Other (-8.4pp).
Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 61% of names.
The largest new positions opened in Q3 2025 were ABVX ($84.90M), RGEN ($53.47M), DXCM ($43.74M).
Of the 19 positions fully exited versus the prior quarter, the largest were GEHC ($51.85M), MLTX ($25.96M), COO ($24.91M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- ABVX ABIVAX SA · $84.90M
- RGEN REPLIGEN CORP · $53.47M
- DXCM DEXCOM INC · $43.74M
- BIIB BIOGEN INC · $38.52M
- RAPP RAPPORT THERAPEUTICS INC · $28.21M
- BLTE BELITE BIO INC · $23.12M
- RARE ULTRAGENYX PHARMACEUTICAL IN · $22.56M
- AXSM AXSOME THERAPEUTICS INC. · $18.22M
Fully Exited (vs previous quarter)
- GEHC GE HEALTHCARE TECHNOLOGIES I · prev qtr: $51.85M
- MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $25.96M · history
- COO COOPER COS INC · prev qtr: $24.91M
- GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $24.89M
- EW EDWARDS LIFESCIENCES CORP · prev qtr: $23.46M
- COGT COGENT BIOSCIENCES INC · prev qtr: $22.11M · history
- MDT MEDTRONIC PLC · prev qtr: $17.00M
- PRGO PERRIGO CO PLC · prev qtr: $16.70M
Insider Transactions (Form 4)
Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-127682 (status: Approved), registered 2023-04-14
- Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: vestalpoint.com
Portfolio Structure
- 63 positions · $3.87B reported value (Q3 2026)
- Top 10 holdings = 67.3% of reported value
- Largest position: ABVX (ABIVAX SA) at 10.1%
- Average position size: $61.44M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
600.00K | $119.29M | 5.39% | Add | |
| 2 |
|
1.25M | $102.62M | 4.63% | Reduce | |
| 3 |
|
1.10M | $95.13M | 4.30% | Add | |
| 4 |
|
1.00M | $84.90M | 3.83% | New | |
| 5 |
|
1.10M | $81.96M | 3.70% | Add | |
| 6 |
|
5.10M | $80.53M | 3.64% | Add | |
| 7 |
|
9.75M | $76.83M | 3.47% | Reduce | |
| 8 |
|
1.25M | $71.59M | 3.23% | Add | |
| 9 |
|
1.07M | $70.33M | 3.18% | Add | |
| 10 |
|
500.00K | $65.90M | 2.98% | Reduce | |
| 11 |
|
325.00K | $60.83M | 2.75% | Add | |
| 12 |
|
1.50M | $55.86M | 2.52% | Hold | |
| 13 |
|
6.35M | $54.10M | 2.44% | Add | |
| 14 |
|
400.00K | $53.47M | 2.42% | New | |
| 15 |
|
1.18M | $46.43M | 2.10% | Reduce | |
| 16 |
|
830.00K | $44.95M | 2.03% | Add | |
| 17 |
|
1.10M | $44.16M | 1.99% | Reduce | |
| 18 |
|
650.00K | $43.74M | 1.98% | New | |
| 19 |
|
725.00K | $39.85M | 1.80% | Reduce | |
| 20 |
|
275.00K | $38.52M | 1.74% | New | |
| 21 |
|
400.00K | $38.30M | 1.73% | Reduce | |
| 22 |
|
4.96M | $36.08M | 1.63% | Add | |
| 23 |
|
2.77M | $35.10M | 1.58% | Add | |
| 24 |
|
2.42M | $33.93M | 1.53% | Reduce | |
| 25 |
|
250.00K | $33.48M | 1.51% | Add | |
| 26 |
|
500.00K | $33.04M | 1.49% | Add | |
| 27 |
|
3.48M | $32.11M | 1.45% | Add | |
| 28 |
|
750.00K | $31.24M | 1.41% | Reduce | |
| 29 |
|
1.21M | $31.17M | 1.41% | Reduce | |
| 30 |
|
1.76M | $30.15M | 1.36% | Add | |
| 31 |
|
150.00K | $29.74M | 1.34% | Add | |
| 32 |
|
630.00K | $29.42M | 1.33% | Reduce | |
| 33 |
|
950.00K | $28.21M | 1.27% | New | |
| 34 |
|
1.16M | $23.75M | 1.07% | Add | |
| 35 |
|
17.23M | $23.60M | 1.07% | Reduce | |
| 36 |
|
312.50K | $23.12M | 1.04% | New | |
| 37 |
|
750.00K | $22.56M | 1.02% | New | |
| 38 |
|
760.00K | $22.09M | 1.00% | Reduce | |
| 39 |
|
3.25M | $21.58M | 0.97% | Add | |
| 40 |
|
5.55M | $21.03M | 0.95% | Reduce | |
| 41 |
|
2.67M | $18.86M | 0.85% | Reduce | |
| 42 |
|
2.98M | $18.36M | 0.83% | Add | |
| 43 |
|
150.00K | $18.22M | 0.82% | New | |
| 44 |
|
5.50M | $17.98M | 0.81% | Add | |
| 45 |
|
425.00K | $16.89M | 0.76% | New | |
| 46 |
|
4.01M | $14.33M | 0.65% | Reduce | |
| 47 |
|
440.00K | $14.30M | 0.65% | Reduce | |
| 48 |
|
25.00K | $14.06M | 0.64% | New | |
| 49 |
|
225.00K | $13.13M | 0.59% | Reduce | |
| 50 |
|
600.00K | $11.92M | 0.54% | Add | |
FAQ
What did Vestal Point Capital, LP buy in 2025-Q3?
In its 2025-Q3 13F filing, Vestal Point Capital, LP reported 81 equity positions worth $2.21B in aggregate; its largest disclosed positions were ASND ($119.29M), ACLX ($102.62M), NUVL ($95.13M).
How large is Vestal Point Capital, LP's portfolio?
Vestal Point Capital, LP reported $2.21B of long equity holdings across 81 positions as of 2025-Q3. Top-10 holdings account for 38.3% of reported value.
What is Vestal Point Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.